Frontlight ResearchEarly access
Mantle cell lymphoma trials in Spain
21 of 21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Active, not recruitingAn early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Where
- Badalona, Barcelona, Madrid, Málaga, Salamanca
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Celgene Corp.
See details and how to joinNCT03930953 · EU 2024-515690-10-00 - Phase 3Taking peopleA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Where
- A Coruña, Barcelona, Cadiz, Murcia
- Age
- 18 years and over
- People
- 182 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06084936 - Phase 1Not yet taking people in SpainA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 215 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00 - Phase 2Taking peopleA study to evaluate acalabrutinib, in combination with the R-CHOP standard of care, for previously untreated mantle cell lymphoma in Spain.
- Where
- A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia, Gijón, Madrid, Málaga, Palma, Salamanca, Santa Cruz de Tenerife, Santander, Sevilla, Valencia, Vigo
- Age
- 18 years and over
- People
- 55
- Run by
- Astrazeneca Farmaceutica Spain S.A.
See details and how to join2025-521152-34-00 - Phase 1Taking peopleIKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Where
- Badalona, Madrid, Salamanca
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659 - Phase 1Not yet taking people in SpainA Study of ARC-02 in B-cell NHL
- Where
- Barcelona, Cáceres, Madrid, Sevilla
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00 - Phase 3Taking peopleA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06742996 · EU 2024-515593-27-00 - Phase 1/2Taking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Barcelona, Madrid, Palma, Santiago de Compostela, Valencia
- Age
- 18 years and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - Phase 2Taking peopleA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
- Where
- A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Gijón, Madrid, Majadahonda, Málaga, Palma de Mallorca, Salamanca, Santa Cruz de Tenerife, Santander, Seville, Valencia, Vigo
- Age
- 18 years to 130 years
- People
- 55
- Run by
- AstraZeneca
See details and how to joinNCT07029737 - Phase 1/2Not yet taking people in SpainA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- L'Hospitalet de Llobregat, Madrid, Salamanca
- Age
- 18 years and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Barcelona, Madrid, Majadahonda, Valencia
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 2Taking peoplePIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA
- Where
- Alicante, Badalona, Barcelona, Granada, Madrid, Santander, Sevilla
- Age
- 18 years and over
- People
- 96 worldwide
- Run by
- Klinikum der Universitaet Muenchen AöR
See details and how to join2024-512922-27-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory Mantle Cell Lymphoma
- Where
- A Coruña, Barcelona, Cadiz, Murcia
- Age
- 18 years and over
- People
- 39 worldwide
- Run by
- F. Hoffmann-La Roche AG
See details and how to join2023-503206-37-00 - Phase 1SuspendedDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- Where
- Madrid, Pamplona
- Age
- 18 years and over
- People
- 85 worldwide
- Run by
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
See details and how to joinNCT06980116 · EU 2024-516869-36-00 - Phase 1Taking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Barcelona, Gijón, Madrid
- Age
- 18 years and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - Phase 1Taking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca
- Age
- 18 years and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00 - Phase 2Taking peopleClinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
- Where
- Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Marbella, Pamplona, Salamanca, Valencia
- Age
- 18 years and over
- People
- 50 worldwide
- Run by
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
See details and how to joinNCT07285590 · EU 2024-511983-97-00 - Phase 1/2Taking peopleIMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED (GENETICALLY MODIFIED) THROUGH A LENTIVIRAL VECTOR TO EXPRESS A CHIMERIC RECEPTOR WITH ANTI-CD19 SPECIFICITY ASSOCIATED WITH CO-STIMULATORY SEQUENCES 4-1-BB AND CD3Ζ IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA.
- Where
- Barcelona, Sevilla
- Age
- 18 years and over
- People
- 40
- Run by
- Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
See details and how to join2024-519790-19-00 - Phase 3Taking peopleA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Where
- Barcelona, Córdoba, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santiago de Compostela, Sevilla, Valencia
- Age
- 60 years and over
- People
- 476 worldwide
- Run by
- InnoCare Pharma Inc.
See details and how to joinNCT06363994 · EU 2025-524241-27-00 - Phase 2Taking peopleCAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca, Sevilla, Valencia
- Age
- 18 years to 75 years
- People
- 150 worldwide
- Run by
- Christian Schmidt, MD
See details and how to joinNCT06482684 · EU 2022-502405-15-01